Allergan plc announced on Monday it recorded a loss per share of $0.97 in the fourth quarter of 2019, improving from a loss per share of $12.83 in the same period in 2018. Similarly, the Irish-based pharmaceutical company had an operating loss of $276 million, up from $5.38 billion in the fourth quarter of the year before. At the same time, total net revenues added 6.6% annually to reach $4.35 billion. Investments in research and development fell 33.3% on an annual basis.
Full-year revenue climbed 1.9% in 2019 to reach $16.09 billion, as net loss shrank by 28.8% to $4.45 billion, the financial update showed. Diluted loss per share for the whole year amounted to $16.02, slightly up from a loss of 15.26 per share in the year prior.
"I am proud of Allergan's colleagues who achieved many important milestones in 2019 that will make a difference to patients for years to come. They achieved FDA approval of UBRELVY, a first-in-class oral treatment for migraine; two new approvals for BOTOX for pediatric spasticity; approval for VRAYLAR for bipolar depression; and filings for two new eye care drugs - Bimatoprost SR for glaucoma and Abicipar for Age-related Macular Degeneration," said CEO Brent Saunders.
